View in EDS HTML Full Text PDF Full Text

Adverse event detection in drug development: recommendations and obligations beyond phase 3.

Saved in:
Bibliographic Details
Title: Adverse event detection in drug development: recommendations and obligations beyond phase 3.
Authors: Berlin JA (AUTHOR), Glasser SC (AUTHOR), Ellenberg SS (AUTHOR)
Source: American Journal of Public Health. Aug2008, Vol. 98 Issue 8, p1366-1371. 6p.
Subjects: Drug development, Pharmacology, Drug side effects, Drug marketing, Medical records, Medical informatics, Pharmacodynamics, Pharmaceutical policy, Clinical trials
Abstract: Prémarketing studies of drugs, although large enough to demonstrate efficacy and detect common adverse events, cannot reliably detectan increased incidence of rare adverse events or events with significant latency. For most drugs, only about 500 to 3000 participants are studied, for relatively short durations, before a drug is marketed. Systems for assessment of postmarketing adverse events include spontaneous reports, computerized claims or medical record databases, and formal postmarketing studies. We briefly review the strengths and limitations of each. Postmarketing surveillance is essential for developing a full understanding of the balance between benefits and adverse effects. More work is needed in analysis of data from spontaneous reports of adverse effects and automated databases, design of ad hoc studies, and design of economically feasible large randomized studies. [ABSTRACT FROM AUTHOR]
Copyright of American Journal of Public Health is the property of American Public Health Association and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 105671991
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Adverse event detection in drug development: recommendations and obligations beyond phase 3.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Berlin+JA%22">Berlin JA</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Glasser+SC%22">Glasser SC</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ellenberg+SS%22">Ellenberg SS</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22American+Journal+of+Public+Health%22">American Journal of Public Health</searchLink>. Aug2008, Vol. 98 Issue 8, p1366-1371. 6p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Drug+development%22">Drug development</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmacology%22">Pharmacology</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+side+effects%22">Drug side effects</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+marketing%22">Drug marketing</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+records%22">Medical records</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+informatics%22">Medical informatics</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmacodynamics%22">Pharmacodynamics</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmaceutical+policy%22">Pharmaceutical policy</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Prémarketing studies of drugs, although large enough to demonstrate efficacy and detect common adverse events, cannot reliably detectan increased incidence of rare adverse events or events with significant latency. For most drugs, only about 500 to 3000 participants are studied, for relatively short durations, before a drug is marketed. Systems for assessment of postmarketing adverse events include spontaneous reports, computerized claims or medical record databases, and formal postmarketing studies. We briefly review the strengths and limitations of each. Postmarketing surveillance is essential for developing a full understanding of the balance between benefits and adverse effects. More work is needed in analysis of data from spontaneous reports of adverse effects and automated databases, design of ad hoc studies, and design of economically feasible large randomized studies. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of American Journal of Public Health is the property of American Public Health Association and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=105671991
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2105/AJPH.2007.124537
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 6
        StartPage: 1366
    Subjects:
      – SubjectFull: Drug development
        Type: general
      – SubjectFull: Pharmacology
        Type: general
      – SubjectFull: Drug side effects
        Type: general
      – SubjectFull: Drug marketing
        Type: general
      – SubjectFull: Medical records
        Type: general
      – SubjectFull: Medical informatics
        Type: general
      – SubjectFull: Pharmacodynamics
        Type: general
      – SubjectFull: Pharmaceutical policy
        Type: general
      – SubjectFull: Clinical trials
        Type: general
    Titles:
      – TitleFull: Adverse event detection in drug development: recommendations and obligations beyond phase 3.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Berlin JA
      – PersonEntity:
          Name:
            NameFull: Glasser SC
      – PersonEntity:
          Name:
            NameFull: Ellenberg SS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: Aug2008
              Type: published
              Y: 2008
          Identifiers:
            – Type: issn-print
              Value: 00900036
          Numbering:
            – Type: volume
              Value: 98
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: American Journal of Public Health
              Type: main
ResultId 1